Vertex Builds Type 1 Diabetes Reach And Flexibility With ViaCyte
Executive Summary
Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.
You may also be interested in...
Vertex Adds To Myotonic Dystrophy Effort With Entrada Collaboration
Entrada gets $250m cash and equity up front under four-year deal, which extends its runway and will enable it to focus on Duchenne muscular dystrophy. Vertex further diversifies its pipeline with a novel drug class.
Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact
Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.